Ludwig Hantson, Alexion via Twitter
So why is Alexion paying $100M for a PRV as AstraZeneca lines up their $39B buyout?
It looks like AstraZeneca may have a bonus waiting once it’s done acquiring Alexion.
Yesterday, Rhythm Pharmaceuticals put out word that the biotech sold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
